Conditions: Type 2 Diabetes
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 22
Healthy volunteers: no

Brief summary:
Sitagliptin is a new oral hypoglycemic anti-diabetic drug used either alone or in combination with metformin or a thiazolidinedione for control of type 2 diabetes mellitus. Sitagliptin has been shown to have fewer side effects in the control of blood glucose values.

Obesity and diabetes are states of increased inflammation and can influence the free radicals and inflammatory markers (chemicals in the blood which increase due to inflammation in the body) and are also major risk factors for atherosclerotic disease. In this study we want to see the effect of sitagliptin on these markers. We believe that Sitagliptin may exert an anti-inflammatory effect in the human. The purpose of this study is to determine if the addition of sitagliptin to diabetic patients will provide added benefit. We believe that sitagliptin provides these added benefits by suppressing free radicals (charged substances that cause damage to the body) and inflammation.

Detailed description:

Arms:
arm 1: The first group will be started on 100 mg sitagliptin daily for 12 weeks arm 2: will be placed on a placebo for 12 weeks.

Interventions: intervention 1: Januvia (Sitagliptin) 100 mg intervention 2: Placebo
Intervention descriptions: intervention 1: The first group will be started on 100 mg sitagliptin daily for 12 weeks intervention 2: will be placed on a placebo for 12 weeks.

Protocol document: